Axsome Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It is also developing AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.

In a report released today, from Jefferies maintained a Buy rating on Axsome Therapeutics, with a price target of $245.00. In addition to Jefferies...

Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

An update from Axsome Therapeutics ( ($AXSM) ) is now available. On April 1, 2026, Axsome Therapeutics announced an asset purchase agreement to acq...

Axsome acquires global rights to Takeda’s balipodect

In a report released today, Yatin Suneja from Guggenheim maintained a Buy rating on Axsome Therapeutics, with a price target of $245.00. According ...

Guggenheim Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Monte Rosa Therapeutics ...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Monte Rosa Therapeutics (GLUE) and Curis (CRIS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolyPid (PYPD) and Axsome Therapeutics (AXSM) with b...

Current Quarter	$-0.85	Next Quarter	$-0.51
Current Year	$-1.15	Next Year	$5.62
QoQ Growth	+40.0%	YoY Growth	+588.7%
3Y EPS CAGR	N/A	Target Price	$224.90
Consensus	Buy	Upside	+19.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AXSM	$188.99	+2.61%	767.28K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AXSM	$188.99	+2.6%	767.28K
3
4
5
6

AXSM

AXSM

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get AXSM Data in Excel

Get AXSM Data in Excel